BofA notes that the Institute for Clinical and Economic Review released its updated draft report for obesity drugs and now says the GLP-1 class as a whole are cost-effective, in a reversal from what ICER had said previously in 2022. The ICER update is a “win” for Eli Lilly (LLY) and its main rival Novo Nordisk (NVO), says the analyst, who sees this analysis as “an important and necessary step” toward securing better employer and payer coverage for GLP-1s. The firm keeps a Buy rating and $900 price target on Eli Lilly shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly launches TuneLab AI-driven drug discovery platform
- Hims Stock (HIMS) Rises as FDA Publishes “Green List,” Novo Nordisk Shares Slip
- Eli Lilly’s (LLY) Leukemia Drug Shows Promise in Clinical Trial
- Eli Lilly reports BRUIN CLL-313 clinical trial meets primary endpoint
- Eli Lilly & Co. Faces Legal and Regulatory Challenges Impacting Market Position and Financial Outlook